Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSITY-HIGH: Alirocumab in Stable Cardiovascular Disease
NCT03355027Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Nov 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of alirocumab in atherosclerosis and cardiovascular disease (CVD) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Vascular inflammation (Standard Uptake Value) - Carotid artery at 8 weeks, Vascular inflammation (Tissue to Background Ratio TBR) - Carotid artery at 8 weeks and 2 more. Status: unknown.
02
Drugs
alirocumab
03
Conditions
atherosclerosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03355027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355027.